Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial
Titel:
Reduction in Hepatocyte Growth Factor Serum Levels is Associated with Improved Prognosis in Advanced Lung Adenocarcinoma Patients Treated with Afatinib: a Phase II Trial
Auteur:
Arrieta, Oscar Cruz-Rico, Graciela Soto-Perez-de-Celis, Enrique Ramírez-Tirado, Laura-Alejandra Caballe-Perez, Enrique Martínez-Hernández, Jorge-Negueb Martinez-Alvarez, Ivan Soca-Chafre, Giovanny Macedo-Pérez, Eleazar Omar Astudillo-de la Vega, Horacio